Holen Sie sich die Stockscreener-App
0.00
100.00%
-5.84
Schlusskurs vom Vortag:
$5.84
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$189.98M
Einnahmen:
$425.17M
Nettoeinkommen (Verlust:
$-92.21M
KGV:
0.00
EPS:
-2.57
Netto-Cashflow:
$-67.42M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$6.85
Nevro Corp Stock (NVRO) Company Profile
Firmenname
Nevro Corp
Sektor
Branche
Telefon
650-251-0005
Adresse
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Vergleichen Sie NVRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
0.00 | 189.98M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
131.37 | 229.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.75 | 157.64B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
389.67 | 150.76B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
91.96 | 118.26B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
81.23 | 47.71B | 5.69B | 1.41B | 577.90M | 6.95 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-03 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-08-09 | Hochstufung | Citigroup | Sell → Neutral |
| 2024-08-08 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-08-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-05-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-12-21 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-05-31 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2023-01-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-12-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Hold |
| 2022-04-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-11-09 | Herabstufung | Truist | Buy → Hold |
| 2021-08-05 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-05 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-07-09 | Herabstufung | Redburn | Buy → Neutral |
| 2021-07-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-08 | Hochstufung | UBS | Sell → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-11-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-10-22 | Eingeleitet | Oppenheimer | Perform |
| 2019-03-20 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-20 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Sell |
| 2018-11-07 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-07-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-05-08 | Bestätigt | Canaccord Genuity | Buy |
| 2018-05-08 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-08 | Herabstufung | Wells Fargo | Outperform → Market Perform |
Alle ansehen
Nevro Corp Aktie (NVRO) Neueste Nachrichten
GMED Q2 Deep Dive: New CEO, Nevro Integration, and Product Pipeline Propel Growth - Yahoo Finance
Globus Medical: A Strategic Powerhouse in the Evolving Spine Care Landscape - AInvest
Decoding Globus Medical Inc (GMED): A Strategic SWOT Insight - GuruFocus
Neurological Implants Market is projected to reach US$ 12.39 - openPR.com
Globus Medical's Leadership Transition and Growth Potential in a Post-Merger Landscape - AInvest
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $200,000 In Nevro Corp. To Contact The Firm - ACCESS Newswire
When the Price of (NVRO) Talks, People Listen - news.stocktradersdaily.com
Neuromodulation Devices Market is projected to reach USD 190.14 - openPR.com
Global Neuromodulation Market to grow at a CAGR of 8.95% by 2030, Evaluates DelveInsight | Medtronic, Abbott, Boston Scientific Corp, LivaNova, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc - Barchart.com
Collegeville Office Buildings Sell to Globus Medical with Staggering Price Cut - DELCO.Today
Zimmer hires former Nevro CEO Kevin Thornal - Yahoo Finance
Zimmer Biomet Taps Growth Expert Kevin Thornal to Lead Global Business Strategy and Americas Operations - Stock Titan
BTIG Downgrades Globus Medical to Neutral From Buy - marketscreener.com
JMP maintains Market Perform on Globus Medical stock By Investing.com - Investing.com India
JMP maintains Market Perform on Globus Medical stock - Investing.com Australia
Price T Rowe Associates Inc. MD Acquires 38,869 Shares of Nevro Corp. (NYSE:NVRO) - Defense World
Globus Medical, Inc. (NYSE:GMED) Q1 2025 Earnings Call Transcript - Insider Monkey
Globus Medical stock target cut to $78 by Oppenheimer - Investing.com Nigeria
Truist cuts Globus Medical stock target to $68, maintains hold By Investing.com - Investing.com Nigeria
Globus Medical’s Strategic Acquisition of Nevro Corp: A Catalyst for Growth and Market Expansion - TipRanks
Nevro to Present at Wells Fargo 2024 Healthcare Conference - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Globus Medical: Strong Execution and Strategic Moves Signal Buy Opportunity Post-Q4 Earnings - AInvest
Globus Medical: Digesting Another Acquisition (NYSE:GMED) - Seeking Alpha
Learn to Evaluate (NVRO) using the Charts - news.stocktradersdaily.com
Nevro Corp. Data Breach under Investigation by Levi & Korsinsky, LLP - Louisiana First News
Nevro Receives CE Mark for Senza II™ Spinal Cord Stimulation System Delivering HF10™ Therapy | Libero Quotidiano.it - Libero Quotidiano
Globus Medical Announces Q1 Earnings Date: Leading Musculoskeletal Tech Firm Reports May 8 - Stock Titan
Nevro (NYSE:NVRO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Levi & Korsinsky, LLP Investigates Nevro Corp. Data Breach - ACCESS Newswire
Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN
Prudential Financial Inc. Grows Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data Breach - ACCESS Newswire
Spinal Cord Stimulator Market to Set Phenomenal Growth From 2025 to 2034 | Medtronic,Boston Scientific,Nevro Corp - openPR.com
GMED Stock May Benefit Following the Acquisition of Nevro - MSN
Raymond James Financial Inc. Invests $287,000 in Nevro Corp. (NYSE:NVRO) - Defense World
Nevro (NYSE:NVRO) Coverage Initiated at StockNews.com - MarketBeat
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating - GlobeNewswire
DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Nevro Corp. Customers Whose Data May Have Been Compromised - TradingView
(NVRO) Trading Report - news.stocktradersdaily.com
Nevro Files Notice of Data Breach Affecting Confidential Consumer Information - JD Supra
Globus acquires US medical device company Nevro - Yahoo Finance
Nevro Data Breach Class Action - databreachclassaction.io
Globus Medical Completes Acquisition of Nevro Corp. - MyChesCo
Nevro Corp. Investigated by Federman & Sherwood for Data Breach - GlobeNewswire
Nevro to Participate in Wells Fargo 2022 MedTech R&D Spotlight Call Series - MarketScreener
Nevro Data Breach Investigation - Claim Depot
Nevro Corp Completes Merger and Delists from NYSE - TipRanks
Finanzdaten der Nevro Corp-Aktie (NVRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):